Zobrazeno 1 - 10
of 2 489
pro vyhledávání: '"A E, Aust"'
Publikováno v:
The British Medical Journal, 1901 Sep 01. 2(2123), 651-652.
Externí odkaz:
https://www.jstor.org/stable/20269487
Autor:
José Luís Félix
Publikováno v:
A Educação no Brasil e no Mundo: Avanços, Limites e Contradições 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f0035a8b6be25a88d5c19d983d66f2a
https://doi.org/10.22533/at.ed.34920200124
https://doi.org/10.22533/at.ed.34920200124
Autor:
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M. S. Hashemi, Urska Janzic, Waleed Kian, Katja Mohorcic, Saara Mohammed, Maria Silvoniemi, Sacha I. Rothschild, Christian Schulz, Claas Wesseler, Alfredo Addeo, Karin Armster, Malinda Itchins, Marija Ivanović, Diego Kauffmann-Guerrero, Jussi Koivunen, Jonas Kuon, Nick Pavlakis, Berber Piet, Martin Sebastian, Janna-Lisa Velthaus-Rusik, Luciano Wannesson, Marcel Wiesweg, Robert Wurm, Corinna Albers-Leischner, Daniela E. Aust, Melanie Janning, Hannah Fabikan, Sylvia Herold, Anna Klimova, Sonja Loges, Yana Sharapova, Maret Schütz, Christoph Weinlinger, Arschang Valipour, Tobias Raphael Overbeck, Frank Griesinger, Marko Jakopovic, Maximilian J. Hochmair, Martin Wermke
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3992 (2024)
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an
Externí odkaz:
https://doaj.org/article/6ed7bccf8a6a4049820a8177574fd8c6
Autor:
Max Heiduk, Ioana Plesca, Jessica Glück, Luise Müller, David Digomann, Charlotte Reiche, Janusz von Renesse, Rahel Decker, Christoph Kahlert, Ulrich Sommer, Daniela E. Aust, Marc Schmitz, Jürgen Weitz, Lena Seifert, Adrian M. Seifert
Publikováno v:
JCI Insight, Vol 7, Iss 22 (2022)
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally a
Externí odkaz:
https://doaj.org/article/9a5a29027fcc4aadb45aea3cef95ab9a
Autor:
Kerschagl, R.
Publikováno v:
Zeitschrift für Nationalökonomie / Journal of Economics, 1960 Jan 01. 20(1/2), 282-282.
Externí odkaz:
https://www.jstor.org/stable/41796104
Autor:
Tareq A. Juratli, Insa Prilop, Felix C. Saalfeld, Sylvia Herold, Matthias Meinhardt, Carina Wenzel, Silke Zeugner, Daniela E. Aust, Fred G. Barker, Daniel P. Cahill, Priscilla K. Brastianos, Sandro Santagata, Gabriele Schackert, Thomas Pinzer
Publikováno v:
Acta Neuropathologica Communications, Vol 9, Iss 1, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/1e680a3127184b6993515635f457bbbd
Autor:
Sebastian Hempel, Florian Oehme, Benjamin Müssle, Daniela E. Aust, Marius Distler, Hans-Detlev Saeger, Jürgen Weitz, Thilo Welsch
Publikováno v:
World Journal of Surgical Oncology, Vol 18, Iss 1, Pp 1-9 (2020)
Abstract Background Resection of the para-aortic lymph node (PALN) group Ln16b1 during pancreatoduodenectomy remains controversial because PALN metastases are associated with a worse prognosis in pancreatic cancer patients. The present study aimed to
Externí odkaz:
https://doaj.org/article/e7d5a7907e2f4ecba6e0c6755412ecb4
Publikováno v:
Surgical Case Reports, Vol 5, Iss 1, Pp 1-6 (2019)
Abstract Background Biliary adenofibroma is an exceptionally rare benign liver tumor with the potential for malignant transformation. In literature, only 21 cases have been described. Clinical presentation In a healthy 63-year-old woman, a partly sol
Externí odkaz:
https://doaj.org/article/c0f3929b59cd4d8ba496c2f52daa0b9c
Autor:
Max Heiduk, Anna Klimova, Charlotte Reiche, David Digomann, Carolin Beer, Daniela E. Aust, Marius Distler, Jürgen Weitz, Adrian M. Seifert, Lena Seifert
Publikováno v:
Clinical Cancer Research.
Purpose: Immunotherapy has led to a fundamental shift in the treatment of several cancers. However, its efficacy in pancreatic ductal adenocarcinoma (PDAC) is limited. Understanding the expression of inhibitory immune checkpoint receptors (ICR) by in
Autor:
Sebastian Hempel, Verena Plodeck, Franz Mierke, Marius Distler, Daniela E. Aust, Hans-Detlev Saeger, Jürgen Weitz, Thilo Welsch
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
Abstract No international consensus regarding the resection of the para-aortic lymph node (PALN) station Ln16b1 during pancreatoduodenectomy for pancreatic ductal adenocarcinoma (PDAC) has been reached. The present retrospectively investigated 264 pa
Externí odkaz:
https://doaj.org/article/d10062847a524af3a9ee1988da84a66d